Format

Send to

Choose Destination
Leukemia. 2019 Mar 7. doi: 10.1038/s41375-019-0437-5. [Epub ahead of print]

Anti-CD19 CAR-T as a feasible and safe treatment against central nervous system leukemia after intrathecal chemotherapy in adults with relapsed or refractory B-ALL.

Author information

1
Nankai University School of Medicine, Tianjin, PR China.
2
Department of hematology, Tianjin First Central Hospital, No. 24 Fu Kang Road, Tianjin, PR China.
3
Tianjin medical university, Tianjin, PR China.
4
Leukemia Center, Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, 288 Nanjing Road, Tianjin, PR China. yanghua94583@sina.com.
5
Nankai University School of Medicine, Tianjin, PR China. mingfengzhao@sina.com.
6
Department of hematology, Tianjin First Central Hospital, No. 24 Fu Kang Road, Tianjin, PR China. mingfengzhao@sina.com.
PMID:
30846865
DOI:
10.1038/s41375-019-0437-5

Supplemental Content

Full text links

Icon for Nature Publishing Group
Loading ...
Support Center